Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management
Journal of Infectious Diseases, Volume 192, No. 6, Year 2005
Notification
URL copied to clipboard!
Description
Background. Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis. Methods. We determined the baseline rate of drug resistance in 2208 therapy-naive patients recently and chronically infected with HIV-1 from 19 European countries during 1996-2002. Results. In Europe, 1 of 10 antiretroviral-naive patients carried viruses with ≥1 drug-resistance mutation. Recently infected patients harbored resistant variants more often than did chronically infected patients (13.5% vs. 8.7%; P = .006). Non-B viruses (30%) less frequently carried resistance mutations than did subtype B viruses (4.8% vs. 12.9%; P < .01). Baseline resistance increased over time in newly diagnosed cases of non-B infection: from 2.0% (1/49) in 1996-1998 to 8.2% (16/194) in 2000-2001. Conclusions. Drug-resistant variants are frequently present in both recently and chronically infected therapy-naive patients. Drug-resistant variants are most commonly seen in patients infected with subtype B virus, probably because of longer exposure of these viruses to drugs. However, an increase in baseline resistance in non-B viruses is observed. These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated. © 2005 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Wensing, Annemarie Marie J.
Netherlands, Utrecht
Eijkman-winkler Center for Microbiology, Infectious Diseases and Inflammation Univeristy Medical Center Utrecht
Netherlands, Utrecht
University Medical Center Utrecht
Van De Vijver, D. A.M.C.
Netherlands, Utrecht
Eijkman-winkler Center for Microbiology, Infectious Diseases and Inflammation Univeristy Medical Center Utrecht
Angarano, Gioacchino
Italy, Foggia
Università Degli Studi Di Foggia
Åsjö, Birgitta
Norway, Bergen
Universitetet I Bergen
Balotta, Claudia
Italy, Milan
Università Degli Studi Di Milano
Boeri, Enzo
Unknown Affiliation
Camacho, Ricardo Jorge
Unknown Affiliation
Chaix, Marie Laure
France, Paris
Hôpital Necker Enfants Malades
Costagliola, Dominique G.
France, Paris
Sorbonne Université
De Luca, Andrea
Unknown Affiliation
Derdelinckx, Inge
Belgium, Leuven
Ku Leuven
Grossman, Zehava
Israel, Tel Hashomer Tel Aviv
Chaim Sheba Medical Center Israel
Hamouda, Osamah
Germany, Berlin
Robert Koch Institute
Hatzakis, Angelos E.
Greece, Athens
School of Medicine
Hemmer, Robert J.P.
Luxembourg, Luxembourg
Centre Hospitalier de Luxembourg
Hoepelman, Andy I.M.
Netherlands, Utrecht
University Medical Center Utrecht
Horban, Andrzéj
Unknown Affiliation
Korn, Klaus
Germany, Erlangen
Friedrich-alexander-universität Erlangen-nürnberg
Kücherer, Claudia
Germany, Berlin
Robert Koch Institute
Leitner, Thomas K.
United States, Los Alamos
Los Alamos National Laboratory
Loveday, Clive
Unknown Affiliation
de-Mendoza, Carmen
Unknown Affiliation
Meyer, Laurence J.
France, Paris
Inserm
Nielsen, Claus M.
Denmark, Copenhagen
Statens Serum Institut
Ormaasen, Vidar
Norway, Oslo
Ulleval University Hospital
Paraskevis, D. N.
Greece, Athens
School of Medicine
Perrin, Luc Henri
Switzerland, Geneva
Hôpitaux Universitaires de Genève
Puchhammer-Stöckl, Elisabeth
Austria, Vienna
Universität Wien
Ruíz, Lídia
Unknown Affiliation
Salminen, Mika O.
Finland, Helsinki
Terveyden ja Hyvinvoinnin Laitos
Schmit, Jean Claude
Luxembourg, Luxembourg
Centre Hospitalier de Luxembourg
Schneider, François
Luxembourg, Luxembourg
Centre Hospitalier de Luxembourg
Schuurman, Rob J.
Netherlands, Utrecht
Eijkman-winkler Center for Microbiology, Infectious Diseases and Inflammation Univeristy Medical Center Utrecht
Soriano, Vicente Vicente
Unknown Affiliation
Stanojevic, Maja
Serbia, Belgrade
University of Belgrade
Vandamme, Anne Mieke
Belgium, Leuven
Ku Leuven
van Laethem, Kristel V.
Belgium, Leuven
Ku Leuven
Yerly, Sabine T.B.D.
Switzerland, Geneva
Hôpitaux Universitaires de Genève
Zazzi, Maurizio
Italy, Siena
Università Degli Studi Di Siena
Boucher, Charles A.B.
Netherlands, Utrecht
Eijkman-winkler Center for Microbiology, Infectious Diseases and Inflammation Univeristy Medical Center Utrecht
Statistics
Citations: 373
Authors: 40
Affiliations: 24
Identifiers
Doi:
10.1086/432916
ISSN:
00221899
Research Areas
Cancer
Infectious Diseases
Study Design
Cross Sectional Study